M

Mass General Brigham

Early-stage life science venture investor

Registered Nurse - Emergency Department

Part-Time
$41.38 - $100/hr+ Differentials + Premiums + Bonuses
Mid
Bachelor's
Newton, MA, USA
In Person
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • Two years of Emergency Department experience is required unless otherwise noted in the job posting.
  • Advanced Cardiovascular Life Support (ACLS), Pediatric Advanced Life Support (PALS), and Crisis Prevention Institute (CPI) certifications are required within the first year of employment.
  • A required Other Certificate/Diploma in Nursing.
  • A required Registered Nurse state license.
  • Demonstrated clinical competence and experience as required by the specific job posting or specialty area.
  • Ability to use the nursing process and evidence-based practice to provide quality patient care throughout the episode of care.
  • Ability to create and maintain a safe and therapeutic environment for patients, self, and coworkers.
  • Ability to participate in performance improvement activities to assure quality nursing practice.
  • Ability to ensure complete, accurate, and timely written communication of patient information.
  • Ability to provide safe, accurate, and timely medication and intravenous administration.
  • Ability to coordinate and collaborate with multidisciplinary team members to facilitate a comprehensive educational plan.
  • Ability to work in patient-care environments with potential exposure to communicable diseases, hazardous materials, human waste, unpleasant elements, dirt, odors, and cramped quarters.
  • Ability to work with angry, agitated, and combative patients.
Responsibilities
  • Provide direct and indirect patient care using the nursing process, including assessment, planning, implementation, and evaluation.
  • Oversee assigned team members and collaborate with a multidisciplinary team to provide population-specific care in accordance with regulations and professional standards.
  • Follow departmental policies and procedures and contribute to the quality of services.
  • Make independent decisions within the scope of nursing practice and keep informed about changes.
  • Assess patients’ physical, psychological, spiritual, cultural, and social needs; recognize symptoms requiring immediate intervention.
  • Provide competent, compassionate, and individualized care that accounts for patients’ needs, abilities, practices, and circumstances.
  • Update knowledge and skills related to populations served.
  • Develop and update individualized plans of care in collaboration with patients, families, significant others, appropriate resources, and multidisciplinary team members.
  • Engage patients, families, and significant others as partners in care; update plans of care and nursing documentation based on ongoing assessments.
  • Implement clinical and technical aspects of care and physicians’ orders in compliance with standards of practice and care.
  • Evaluate patient and family responses to goals and interventions, and revise plans of care based on those evaluations.
  • Set priorities when planning and implementing patient care.
  • Coordinate discharge planning with appropriate resources and multidisciplinary team members, collaborate with case managers to anticipate discharge needs and address barriers, and include the person primarily responsible for care at home in teaching and discharge planning.
  • Recognize changes in patients’ physical and mental status and inform physicians or other healthcare professionals.
  • Maintain a safe and therapeutic environment; use two patient identifiers; follow infection-control, universal-precaution, OSHA, hazardous-material, and isolation procedures; and safeguard confidential information and privacy.
  • Provide patient comfort and hygiene, use equipment and supplies properly, assess the need for restraints and use alternatives when appropriate, perform point-of-care testing with proper technique and equipment calibration, and ensure equipment is operational and safe.
  • Respond appropriately to emergencies and minimize injury risks through fall precautions and other safety practices.
  • Treat patients and families respectfully and without judgment, advocate for patients, explain their rights and responsibilities, and provide emotional, psychological, and spiritual support.
  • Participate in performance-improvement activities, incorporate recommendations into daily practice, evaluate patient-care outcomes, and recommend appropriate revisions to individualized plans of care.
  • Control patient-care costs through efficient management of supplies and services and suggestions for cost containment.
  • Communicate patient information completely, accurately, and promptly; complete required documentation; document discharge instructions and patient progress in an organized, chronologically accurate format.
  • Administer medications and intravenous fluids safely and promptly; follow the five rights of medication administration; scan patient, medication, and staff barcodes where applicable; and recognize drug actions and appropriate interventions for adverse reactions.
  • Verify or rectify medication records, assess medication and infusion orders for appropriateness, confirm correct drug, dose, and pump settings for continuous large-volume infusions, patient-controlled analgesia, or epidurals, report medication variances, and ensure correct infusion rates.
  • Assess patient and family education needs, formulate and implement an educational plan that accounts for learning barriers and cultural or spiritual needs, document education, evaluate its outcomes, elicit feedback, and modify instruction as needed.
  • Take responsibility for professional performance and development; maintain clinical competence, mandatory training, and regulatory requirements; and accept accountability for assigned patient care.
  • Initiate and facilitate changes to improve nursing-care quality on the unit, collaborate with coworkers and healthcare-team members, and learn from constructive criticism.
  • Perform charge-nurse duties as needed, act as a resource and professional role model for peers and students, and assist with orientation and ongoing support of new staff.
  • Escalate patient-care concerns through the chain of command and manage urgent and emergent situations effectively.
  • Communicate expectations to assigned team members clearly and tactfully, address conflicts with appropriate personnel, and ensure critical patient information is communicated across the continuum of care.
  • Support and promote management decisions, goals, and initiatives.
  • For the Device Clinic RN role, enroll, interrogate, and program outpatient pacemaker patients; recognize abnormalities, malfunctions, and end-of-service indicators; notify cardiologists and assist with follow-up or replacement scheduling.
  • For the Device Clinic RN role, coordinate and prioritize timely care with healthcare-team members; educate patients and families about device function and clinic follow-up; forward information to referring physicians; and ensure timely, proper documentation and billing.
  • For the Device Clinic RN role, lead the device-recall team; manage administrative duties for device trans-telephonic monitoring, including purchase orders, billing issues, and reporting; oversee Cardiac Arrhythmia Service event monitoring; provide cross-coverage; serve as a resource to staff, departments, and administration; provide input and recommendations on budgetary goals; maintain knowledge of policies and regulatory requirements; and participate in continuing education.
  • For the STAT RN role, assist with rapid responses and Code Blue events on inpatient units.
  • For the STAT RN role, assist with admissions and transfers of critically ill patients to the intensive care unit from the Emergency Department, Operating Room, Post-Anesthesia Care Unit, medical/surgical units, or Labor and Delivery/Post-Partum units.
  • For the STAT RN role, assist with care of unstable or critically ill, intensive-care-level patients in the Emergency Department, Post-Anesthesia Care Unit, and medical/surgical units as needed; assist with intravenous access and phlebotomy; and assist in the intensive care unit when census or acuity exceeds core staffing and additional resources are unavailable.
  • For the STAT RN role, assist with transport and supervision of patients requiring diagnostic testing off the unit and perform other assigned clinical duties when there are no critical-care support needs in the hospital.
  • For the STAT RN role, work under the direct supervision of the Nursing Administrator and overall direction of the intensive care nurse manager.
Desired Qualifications
  • A Bachelor's Degree in Nursing is preferred.
  • HRS/NASP certification is preferred.
  • Certified Emergency Nurse (CEN) or Critical Care Registered Nurse (CCRN) certification is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

Associated Press
May 13th, 2026
Violet Therapeutics raises $4.75M to advance synaptic preservation therapy for neurodegenerative diseases

Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.